Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Praises PMA-Acceptance Draft Guidance, But Offers A Few Suggestions

This article was originally published in The Gray Sheet

Executive Summary

Companies are generally happy with FDA’s July 31 draft guidance describing a 15-day "acceptance review" that FDA staff will perform to quickly check that a PMA submission meets minimum requirements.


Related Content

FDA Finalizes 510(k), PMA, eCopy Guidances
Washington Roundup, October 2012
Industry Says FDA’s “Refuse To Accept” 510(k) Guidance Is Too Subjective
FDA Charges Ahead With MDUFA III Implementation, Despite Budget Uncertainties
FDA Focuses On Weeding Out Deficient PMAs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts